Bristol-Myers Squibb Company
) is scheduled to release its first quarter 2014 results before
the opening bell on Tuesday, Apr 29. Last quarter, Bristol-Myers
had posted a positive earnings surprise of 18.60%. Let's see how
things are shaping up for this announcement.
ACTAVIS PLC (ACT): Free Stock Analysis Report
BRISTOL-MYERS (BMY): Free Stock Analysis
HOSPIRA INC (HSP): Free Stock Analysis Report
TEVA PHARM ADR (TEVA): Free Stock Analysis
To read this article on Zacks.com click here.
Factors at Play
Bristol-Myers has delivered positive earnings surprises in two of
the last four quarters with an average beat of 11.58%. Drugs like
Baraclude (hepatitis B virus), Sustiva (HIV), Sprycel (leukemia),
Yervoy (skin cancer) and Erbitux (oncology), which performed
encouragingly last quarter are expected to perform well in the
first quarter as well. Moreover, the newly launched products,
especially in the oncology field, are expected to play a key role
in boosting the company's bottom line this quarter. We note that
Bristol-Myers has been trying to offset declining sales of some
of its important products by bringing in new products through
Our proven model however does not conclusively show that
Bristol-Myers is likely to beat earnings this quarter. That is
because a stock needs to have both a positive Earnings ESP
(Expected Surprise Prediction) and a Zacks Rank of #1, 2 or 3 for
this to happen. That is not the case here as you will see below.
for Bristol-Myers is 0.00% since the Most Accurate Estimate
stands at 44 cents, in line with the Zacks Consensus Estimate.
Zacks Rank #3 (Hold):
Bristol-Myers' Zacks Rank #3 when combined with a 0.00% ESP makes
surprise prediction difficult.
Other Stocks to Consider
Here are some companies you may want to consider as our model
shows that they have the right combination of elements, i.e., a
positive Zacks Earnings ESP and a Zacks Rank #1, #2 or #3:
) has an Earnings ESP of +4.08% and holds a Zacks Rank #3.
Hospira will be reporting first quarter earnings before the
opening bell on Apr 30.
Teva Pharmaceutical Industries Limited
) has an Earnings ESP of +0.82% and holds a Zacks Rank #2 (Buy).
Teva will be reporting first quarter earnings on May 1 before
) has an Earnings ESP of +3.34% and holds a Zacks Rank #2.
Actavis will be reporting first quarter earnings on Apr 30 before